Document is current
Any future updates will be listed below
-
Authors
Ramírez-Fernández, Ángel https://orcid.org/0000-0002-3265-6878
Dimitri, Alexander J.
Chen, Fang https://orcid.org/0000-0002-1719-3887
Bartoszek, Robert
Chen, Gregory M.
Córdoba-Espejo, Laura
Zhou, Yuqi
Tang, Yun-hsin
Lin, Chien-Ting https://orcid.org/0000-0001-9467-4505
Acosta, Reyes
Scholler, John
Ghilardi, Guido
Porazzi, Patrizia https://orcid.org/0000-0002-1372-7482
Pellicer, Mireia
Profitós-Pelejà, Núria https://orcid.org/0000-0001-8923-6025
Barta, Stefan K.
Chew, Anne
Jadlowsky, Julie K. https://orcid.org/0009-0005-5115-1321
Gonzalez, Vanessa E.
Siegel, Donald L. https://orcid.org/0000-0003-2098-2251
Levine, Bruce L. https://orcid.org/0000-0001-6971-8465
Roué, Gaël https://orcid.org/0000-0003-0245-2257
Ruella, Marco https://orcid.org/0000-0003-4301-5811
Lotze, Michael T.
June, Carl H. https://orcid.org/0000-0003-0241-3557
Riley, James L. https://orcid.org/0000-0002-1057-576X
Fraietta, Joseph A. https://orcid.org/0000-0001-7900-8993
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 2 September 2025
First Online: 21 October 2025
Competing interests
: A.C.: co-founder and equity holder in Tmunity Therapeutics. D.L.S.: founder’s equity and licensed IP with Verismo Therapeutics, Vetigenics and Chimeric Therapeutics. B.L.L.: consultancy and advisory roles with Terumo, GSK and Kite; co-founder and equity holder in Tmunity Therapeutics (acquired by Kite) and Capstan Therapeutics; advisory board memberships with Avectas, Capstan (Chair), Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, Thermo Fisher Pharma Services and UTC Therapeutics; member of the Alliance for Cancer Gene Therapy Board of Directors. M.R.: holds patents related to CD19 CAR T cells; consultant for NanoString, Bristol Myers Squibb, GlaxoSmithKline, Scailyte, Bayer and AbClon; research funding from AbClon, NanoString, Oxford NanoImaging, viTToria Biotherapeutics, CURIOX and Beckman Coulter; scientific founder of viTToria Biotherapeutics. C.H.J.: receives royalties from Novartis and Kite paid to the University of Pennsylvania; scientific co-founder and equity holder in Capstan Therapeutics, Dispatch Biotherapeutics and BlueWhale Bio; board member of AC Immune; scientific advisory roles with various companies, including BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite, Poseida, Verismo, Viracta and WIRB-Copernicus Group. J.L.R.: received grants from Tmunity/Kite outside of the submitted work; co-founder of Tmunity Therapeutics and BlueWhale Bio with monetary compensation and equity. J.A.F.: holds patents and intellectual property in T cell-based cancer immunotherapy with royalties; receives funding from Tmunity Therapeutics and Danaher Corporation; consultancy with Retro Biosciences; scientific advisory board memberships with Cartography Bio, Shennon Biotechnologies Inc., CellFe Biotech, OverT Bio, Inc., and Tceleron Therapeutics, Inc. All other authors declare no competing interests. G.R.: received grants from Onconova Therapeutics outside of the submitted work.
